Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: Implications for drug therapy

Cell Transplantation

Volumn 16, Issue 3, 2007, Pages 285-299

  Desai, Brinda S ^a   Monahan, Angela J ^a   Carvey, Paul M ^a   Hendey, Bill ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Permeability; Progression; Therapeutics; Tight junction

Indexed keywords

BENSERAZIDE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; ENTACAPONE; GALANTAMINE; LEVODOPA; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE; ROFECOXIB; TACRINE; TALCOPONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG EFFICACY; HUMAN; INFLAMMATION; MEMBRANE PERMEABILITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TIGHT JUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

ALZHEIMER DISEASE; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DISEASE PROGRESSION; HUMANS; PARKINSON DISEASE;

EID: 34250623663     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000007783464731     Document Type: Conference Paper

References (128)

1. Abbott, N. J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200:629-638; 2002.
2. Alafuzoff, I.; Adolfsson, R.; Grundke-Iqbal, I.; Winblad, B. Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol. (Berl.) 73:160-166; 1987.
3. Baba, Y.; Kuroiwa, A.; Uitti, R. J.; Wszolek, Z. K.; Yamada, T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat. Disord. 11:493-498; 2005.
4. Baik, E. J.; Kim, E. J.; Lee, S. H.; Moon, C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 843:118-129; 1999.
5. Banks, W. A. Blood-brain barrier transport of cytokines: A mechanism for neuropathology. Curr. Pharm. Des. 11:973-984; 2005.
6. Banks, W. A. The dam breaks: Disruption of the blood-brain barrier in diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 291:H2595-2596; 2006.
7. Banks, W. A.; Robinson, S. M.; Verma, S.; Morley, J. E. Efflux of human and mouse amyloid beta proteins 1-40 and 1-42 from brain: Impairment in a mouse model of Alzheimer's disease. Neuroscience 121:487-492; 2003.
8. Barcia, C.; de Pablos, V.; Bautista-Hernandez, V.; Sanchez-Bahillo, A.; Bernal, I.; Fernandez-Villalba, E.; Martin, J.; Banon, R.; Fernandez-Barreiro, A.; Herrero, M. T. Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat. Disord. 11:435-439; 2005.
9. Barcia, C.; Emborg, M. E.; Hirsch, E. C.; Herrero, M. T. Blood vessels and parkinsonism. Front. Biosci. 9:277-282; 2004.
10. Barcia, C.; Fernandez Barreiro, A.; Poza, M.; Herrero, M. T. Parkinson's disease and inflammatory changes. Neurotox. Res. 5:411-418; 2003.
11. Barcia, C.; Sanchez Bahillo, A.; Fernandez-Villalba, E.; Bautista, V.; Poza, Y. P. M.; Fernandez-Barreiro, A.; Hirsch, E. C.; Herrero, M. T. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46:402-409; 2004.
12. Bauer, H. C.; Bauer, H. Neural induction of the blood-brain barrier: Still an enigma. Cell. Mol. Neurobiol. 20:13-28; 2000.
13. Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O.; Jellinger, K.; Seitelberger, F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:415-455; 1973.
14. Blennow, K.; de Leon, M. J.; Zetterberg, H. Alzheimer's disease. Lancet 368:387-403; 2006.
15. Blum, D.; Chtarto, A.; Tenenbaum, L.; Brotchi, J.; Levivier, M. Clinical potential of minocycline for neurodegenerative disorders. Neurobiol. Dis. 17:359-366; 2004.
16. Bolton, S. J.; Anthony, D. C.; Perry, V. H. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 86:1245-1257; 1998.
17. Braak, H.; Ghebremedhin, E.; Rub, U.; Bratzke, H.; Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318:121-134; 2004.
18. Buckwalter, M. S.; Coleman, B. S.; Buttini, M.; Barbour, R.; Schenk, D.; Games, D.; Seubert, P.; Wyss-Coray, T. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J. Neurosci. 26:11437-11441; 2006.
19. Canudas, A. M.; Friguls, B.; Planas, A. M.; Gabriel, C.; Escubedo, E.; Camarasa, J.; Camins, A.; Pallas, M. MPP(+) injection into rat substantia nigra causes secondary glial activation but not cell death in the ipsilateral striatum. Neurobiol. Dis. 7:343-361; 2000.
20. Carta, M.; Lindgren, H. S.; Lundblad, M.; Stancampiano, R.; Fadda, F.; Cenci, M. A. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96:1718-1727; 2006.
21. Carvey, P. M.; McRae, A.; Lint, T. F.; Ptak, L. R.; Lo, E. S.; Goetz, C. G.; Klawans, H. L. The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology 41:53-60; 1991.
22. Carvey, P. M.; McRae, A.; Ptak, L. R.; Kao, L. C.; Lo, E. S.; Goetz, C. G.; Tanner, C. M.; Penn, R. D.; Klawans, H. L. Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: Relationship to a striatal-derived DA neuron trophic factor. Prog. Brain Res. 82:693-697; 1990.
23. Carvey, P. M.; Punati, A.; Newman, M. B. Progressive dopamine neuron loss in Parkinson's disease: The multiple hit hypothesis. Cell Transplant. 15:239-250; 2006.
24. Carvey, P. M.; Zhao, C. H.; Hendey, B.; Lum, H.; Trachtenberg, J.; Desai, B. S.; Snyder, J.; Zhu, Y. G.; Ling, Z. D. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur. J. Neurosci. 22:1158-1168; 2005.
25. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.; Huang, X.; Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; Masters, C. L.; Bush, A. I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676; 2001.
26. Claudio, L. Ultrastractural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neuropathol. (Berl.) 91:6-14; 1996.
27. Dahlstrom, A.; Wigander, A.; Lundmark, K.; Gottfries, C. G.; Carvey, P. M.; McRae, A. Investigations on autoantibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. J. Neural Transm. Suppl. 29:195-206; 1990.
28. Deli, M. A.; Abraham, C. S.; Kataoka, Y.; Niwa, M. Permeability studies on in vitro blood-brain barrier models: Physiology, pathology, and pharmacology. Cell. Mol. Neurobiol. 25:59-127; 2005.
29. Desai, B. S.; Zhao, C. H.; Schneider, J. A.; Carvey, P. M.; Hendey, B. Evidence of BBB disruption in Alzheimer's and Parkinson's disease. Soc. Neurosci. Abstr.; 2006.
30. Dickstein, D. L.; Biron, K. E.; Ujiie, M.; Pfeifer, C. G.; Jeffries, A. R.; Jefferies, W. A. A beta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. FASEB J. 20:426-433; 2006.
31. Dohgu, S.; Takata, F.; Yamauchi, A.; Nakagawa, S.; Egawa, T.; Naito, M.; Tsuruo, T.; Sawada, Y.; Niwa, M.; Kataoka, Y. Brain pericytes contribute to the induction and up-regulation of blood-brain barrier functions through transforming growth factor-beta production. Brain Res. 1038:208-215; 2005.
32. Ehrlich, P. Ueber die beziehungen von chemischer constitution, verteilung und pharmakologischer wirkung. Gesammelte Arbeiten zur Immunitaetsforschung 574; 1904.
33. Fabry, Z.; Waldschmidt, M. M.; Hendrickson, D.; Keiner, J.; Love-Homan, L.; Takei, F.; Hart, M. N. Adhesion molecules on murine brain microvascular endothelial cells: Expression and regulation of ICAM-1 and Lgp 55. J. Neuroimmunol. 36:1-11; 1992.
34. Farkas, E.; Luiten, P. G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog. Neurobiol. 64:575-611; 2001.
35. Farrer, M. J.; Haugarvoll, K.; Ross, O. A.; Stone, J. T.; Milkovic, N. M.; Cobb, S. A.; Whittle, A. J.; Lincoln, S. J.; Hulihan, M. M.; Heckman, M. G.; White, L. R.; Aasly, J. O.; Gibson, J. M.; Gosal, D.; Lynch, T.; Wszolek, Z. K.; Uitti, R. J.; Toft, M. Genomewide association, Parkinson disease, and PARK10. Am. J. Hum. Genet. 78:1084-1088; 2006.
36. Faucheux, B. A.; Bonnet, A. M.; Agid, Y.; Hirsch, E. C. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353:981-982; 1999.
37. Fenstermacher, J.; Gross, P.; Sposito, N.; Acuff, V.; Pettersen, S.; Gruber, K. Structural and functional variations in capillary systems within the brain. Ann. NY Acad. Sci. 529:21-30; 1988.
38. Fillmore, H. L.; Holloway, K. L.; Gillies, G. T. Cell replacement efforts to repair neuronal injury: A potential paradigm for the treatment of Parkinson's disease. Neurorehabilitation 20:233-242; 2005.
39. Fiszer, U. Does Parkinson's disease have an immunological basis? The evidence and its therapeutic implications. BioDrugs 15:351-355; 2001.
40. Forster, C.; Silwedel, C.; Golenhofen, N.; Burek, M.; Kietz, S.; Mankertz, J.; Drenckhahn, D. Occludin as direct target for glucocorticoid- induced improvement of blood-brain barrier properties in a murine in vitro system. J. Physiol. 565:475-486; 2005.
41. Frohman, E. M.; Frohman, T. C.; Gupta, S.; de Fougerolles, A.; van den Noort, S. Expression of intercellular adhesion molecule 1 (ICAM-1) in Alzheimer's disease. J. Neurol. Sci. 106:105-111; 1991.
42. Furano, T.; Landi, M. T.; Ceroni, M.; Caporaso, N.; Bernucci, I.; Nappi, G.; Martignoni, E.; Schaeffeler, E.; Eichelbaum, M.; Schwab, M.; Zanger, U. M. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12:529-534; 2002.
43. Gaillard, P. J.; van der Sandt, I. C.; Voorwinden, L. H.; Vu, D.; Nielsen, J. L.; de Boer, A. G.; Breimer, D. D. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm. Res. 17:1198-1205; 2000.
44. Gearing, M.; Schneider, J. A.; Rebeck, G. W.; Hyman, B. T.; Mirra, S. S. Alzheimer's disease with and without coexisting Parkinson's disease changes: Apolipoprotein E genotype and neuropathologic correlates. Neurology 45:1985-1990; 1995.
45. Goldmann, E. Vitalfarbung am zentralnervensystem. Abhandl Konigl preuss Akad Wiss 1:1-60; 1913.
46. Gotz, J.; Ittner, L. M.; Schonrock, N. Alzheimer's disease and frontotemporal dementia: Prospects of a tailored therapy? Med. J. Aust. 185:381-384; 2006.
47. Haglund, M.; Kalaria, R.; Slade, J. Y.; Englund, E. Differential deposition of amyloid beta peptides in cerebral amyloid angiopathy associated with Alzheimer's disease and vascular dementia. Acta Neuropathol. (Berl.) 111:430-435; 2006.
48. Hartz, A. M.; Bauer, B.; Flicker, G.; Miller, D. S. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol. 69:462-470; 2006.
49. Haseloff, R. F.; Blasig, I. E.; Bauer, H. C.; Bauer, H. In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell. Mol. Neurobiol. 25:25-39; 2005.
50. Haussermann, P.; Kuhn, W.; Przuntek, H.; Muller, T. Integrity of the blood-cerebrospinal fluid barrier in early Parkinson's disease. Neurosci. Lett. 300:182-184; 2001.
51. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478; 2000.
52. Huber, J. D.; Vangilder, R. L.; Houser, K. A. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am. J. Physiol. Heart Circ. Physiol. 291:H2660-2668; 2006.
53. Hunot, S.; Hirsch, E. C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 53(Suppl. 3):S49-60; 2003.
54. Iwasaki, T.; Kanda, T.; Mizusawa, H. Effects of pericytes and various cytokines on integrity of endothelial monolayer originated from blood-nerve barrier: An in vitro study. J. Med. Dent. Sci. 46:31-40; 1999.
55. Jonkers, N.; Sarre, S.; Ebinger, G.; Michotte, Y. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J. Neural Transm. 108:559-570; 2001.
56. Kago, T.; Takagi, N.; Date, I.; Takenaga, Y.; Takagi, K.; Takeo, S. Cerebral ischemia enhances tyrosine phosphorylation of occludin in brain capillaries. Biochem. Biophys. Res. Commun. 339:1197-1203; 2006.
57. Kalaria, R. N. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 4:226-260; 1992.
58. Kalaria, R. N.; Cohen, D. L.; Premkumar, D. R.; Nag, S.; LaManna, J. C.; Lust, W. D. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res. Mol. Brain Res. 62:101-105; 1998.
59. Kalaria, R. N.; Harik, S. I. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J. Neurochem. 53:1083-1088; 1989.
60. Kemper, E. M.; Boogerd, W.; Thuis, I.; Beijnen, J. H.; van Tellingen, O. Modulation of the blood-brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumours? Cancer Treat. Rev. 30:415-423; 2004.
61. Kniesel, U.; Wolburg, H. Tight junctions of the blood-brain barrier. Cell. Mol. Neurobiol. 20:57-76; 2000.
62. Kortekaas, R.; Maguire, R. P.; Cremers, T. I.; Dijkstra, D.; van Waarde, A.; Leenders, K. L. In vivo binding behavior of dopamine receptor agonist (+)-PD 128907 and implications for the "ceiling effect" in endogenous competition studies with [(11)C]raclopride - a positron emission tomography study in Macaca mulatta. J. Cereb. Blood How Metab. 24:531-535; 2004.
63. Krizbai, I. A.; Bauer, H.; Bresgen, N.; Eckl, P. M.; Farkas, A.; Szatmari, E.; Traweger, A.; Wejksza, K.; Bauer, H. C. Effect of oxidative stress on the junctional proteins of cultured cerebral endothelial cells. Cell. Mol. Neurobiol. 25:129-139; 2005.
64. Kurkowska-Jastrzebska, I.; Wronska, A.; Kohutnicka, M.; Czlonkowski, A.; Czlonkowska, A. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156:50-61; 1999.
65. Langston, J. W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 47:S153-160; 1996.
66. Larsen, N.; Hastings, T. Inflammation and blood-brain barrier disruption following intrastriatal dopamine or 6-hydroxydopamine injections. Soc. Neurosci. Abstr.; 2005.
67. Liebner, S.; Fischmann, A.; Rascher, G.; Duffner, F.; Grote, E. H.; Kalbacher, H.; Wolburg, H. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. (Berl.) 100:323-331; 2000.
68. Lindvall, O.; Björklund, A. Cell therapy in Parkinson's disease. NeuroRx 1:382-393; 2004.
69. Lio, D.; Annoni, G.; Licastro, F.; Crivello, A.; Forte, G. I.; Scola, L.; Colonna-Romano, G.; Candore, G.; Arosio, B.; Galimberti, L.; Vergani, C.; Caruso, C. Tumor necrosis factor-alpha -308A/G polymorphism is associated with age at onset of Alzheimer's disease. Mech. Ageing Dev. 127:567-571; 2006.
70. Liu, G.; Garrett, M. R.; Men, P.; Zhu, X.; Perry, G.; Smith, M. A. Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta 1741:246-252; 2005.
71. Lush, C. W.; Kvietys, P. R. Microvascular dysfunction in sepsis. Microcirculation 7:83-101; 2000.
72. Man, S. M.; Ma, Y. R.; Shang, D. S.; Zhao, W. D.; Li, B.; Guo, D. W.; Fang, W. G.; Zhu, L.; Chen, Y. H. Peripheral T cells overexpress MIP-1alpha to enhance its transendothelial migration in Alzheimer's disease. Neurobiol. Aging 28:485-496; 2007.
73. Marco, S.; Skaper, S. D. Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci. Lett. 401:219-224; 2006.
74. Maubant, S.; Saint-Dizier, D.; Boutillon, M.; Perron-Sierra, F.; Casara, P. J.; Hickman, J. A.; Tucker, G. C.; Van Obberghen-Schilling, E. Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells. Blood 108:3035-3044; 2006.
75. McGeer, P. L.; Akiyama, H.; Itagaki, S.; McGeer, E. G. Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16:516-527; 1989.
76. McGeer, P. L.; Itagaki, S.; Boyes, B. E.; McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291; 1988.
77. McGeer, P. L.; McGeer, E. G. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21:195-218; 1995.
78. McGuire, S. O.; Ling, Z. D.; Lipton, J. W.; Sortwell, C. E.; Collier, T. J.; Carvey, P. M. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169:219-230; 2001.
79. Mecocci, P.; Parnetti, L.; Reboldi, G. P.; Santucci, C.; Gaiti, A.; Ferri, C.; Gemini, I.; Romagnoli, M.; Cadini, D.; Senin, U. Blood-brain-barrier in a geriatric population: Barrier function in degenerative and vascular dementias. Acta Neurol. Scand. 84:210-213; 1991.
80. Miklossy, J.; Doudet, D. D.; Schwab, C.; Yu, S.; McGeer, E. G.; McGeer, P. L. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 197:275-283; 2006.
81. Mooradian, A. D.; Chung, H. C.; Shah, G. N. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol. Aging 18:469-474; 1997.
82. Nakada, M. T.; Tam, S. H.; Woulfe, D. S.; Casper, K. A.; Swerlick, R. A.; Ghrayeb, J. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes. Commun. 5:491-503; 1998.
83. Nakayama, M.; Uchimura, K.; Zhu, R. L.; Nagayama, T.; Rose, M. E.; Stetler, R. A.; Isakson, P. C.; Chen, J.; Graham, S. H. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. USA 95:10954-10959; 1998.
84. Nicoll, J. A.; Mrak, R. E.; Graham, D. I.; Stewart, J.; Wilcock, G.; MacGowan, S.; Esiri, M. M.; Murray, L. S.; Dewar, D.; Love, S.; Moss, T.; Griffin, W. S. Association of interleukin-1 gene polymorphisms with Alzheimer's disease. Ann. Neurol. 47:365-368; 2000.
85. Nitta, T.; Hata, M.; Gotoh, S.; Seo, Y.; Sasaki, H.; Hashimoto, N.; Furase, M.; Tsukita, S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161:653-660; 2003.
86. Oldendorf, W. H.; Cornford, M. E.; Brown, W. J. The large apparent work capability of the blood-brain barrier: A study of the mitochondrial content of capillary endothelial cells in brain and other tissues of the rat. Ann. Neurol. 1:409-417; 1977.
87. Parachikova, A.; Agadjanyan, M. G.; Cribbs, D. H.; Blurton-Jones, M.; Perreau, V.; Rogers, J.; Beach, T. G.; Cotman, C. W. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging; 2006.
88. Poduslo, J. F.; Curran, G. L. Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier. Neuroreport 12:3197-3200; 2001.
89. Poduslo, J. F.; Curran, G. L.; Wengenack, T. M.; Malester, B.; Duff, K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:555-567; 2001.
90. Prat, A.; Biernacki, K.; Wosik, K.; Antel, J. P. Glial cell influence on the human blood-brain barrier. Glia 36:145-155; 2001.
91. Reynolds, D. S.; Morton, A. J. Changes in blood-brain barrier permeability following neurotoxic lesions of rat brain can be visualised with trypan blue. J. Neurosci. Methods 79:115-121; 1998.
92. Rinne, U. K.; Molsa, P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology 29:1584-1589; 1979.
93. Rogers, J.; Cooper, N. R.; Webster, S.; Schultz, J.; McGeer, P. L.; Styren, S. D.; Civin, W. H.; Brachova, L.; Bradt, B.; Ward, P.; et al. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 89:10016-10020; 1992.
94. Rogers, J.; Strohmeyer, R.; Kovelowski, C. J.; Li, R. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 40:260-269; 2002.
95. Rosenberg, P. B. Clinical aspects of inflammation in Alzheimer's disease. Int. Rev. Psychiatry 17:503-514; 2005.
96. Rota, E.; Bellone, G.; Rocca, P.; Bergamasco, B.; Emanuelli, G.; Ferrero, P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27:33-39; 2006.
97. Rubin, L. L.; Staddon, J. M. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 22:11-28; 1999.
98. Samanta, M. K.; Wilson, B.; Santhi, K.; Sampath Kumar, K. P.; Suresh, B. Alzheimer disease and its management: A review. Am. J. Ther. 13:516-526; 2006.
99. Sayre, L. M.; Perry, G.; Atwood, C. S.; Smith, M. A. The role of metals in neurodegenerative diseases. Cell. Mol. Biol. (Noisy-le-grand) 46:731-741; 2000.
100. Schapira, A.; Olanow, C. W. Principles of treatment in Parkinson's disease. Philadelphia: Elsevier; 2005.
101. Schinkel, A. H.; Smit, J. J.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A.; van der Valk, M. A.; Robanus-Maandag, E. C.; te Riele, H. P.; et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502; 1994.
102. Sedlakova, R.; Shivers, R. R.; Del Maestro, R. F. Ultrastructure of the blood-brain barrier in the rabbit. J. Submicrosc. Cytol. Pathol. 31:149-161; 1999.
103. Shen, H.; Kannari, K.; Yamato, H.; Arai, A.; Matsunaga, M. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J. Exp. Med. 199:149-159; 2003.
104. Shibata, M.; Yamada, S.; Kumar, S. R.; Calero, M.; Bading, J.; Frangione, B.; Holtzman, D. M.; Miller, C. A.; Strickland, D. K.; Ghiso, J.; Zlokovic, B. V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106:1489-1499; 2000.
105. Simpson, I. A.; Vannucci, S. J. Glucose transport into brain: Effects of hypoglycemia. Diabetes Nutr. Metab. 15:281-284; 2002.
106. Skoog, I.; Wallin, A.; Fredman, P.; Hesse, C.; Aevarsson, O.; Karlsson, I.; Gottfries, C. G.; Blennow, K. A population study on blood-brain barrier function in 85-year-olds: Relation to Alzheimer's disease and vascular dementia. Neurology 50:966-971; 1998.
107. Stevenson, B. R.; Keon, B. H. The tight junction: Morphology to molecules. Annu. Rev. Cell Dev. Biol. 14:89-109; 1998.
108. Streit, W. J. Microglia and Alzheimer's disease pathogenesis. J. Neurosci. Res. 77:1-8; 2004.
109. Streit, W. J.; Mrak, R. E.; Griffin, W. S. Microglia and neuroinflammation: A pathological perspective. J. Neuroinflammation 1:14; 2004.
110. Tarkowski, E.; Issa, R.; Sjogren, M.; Wallin, A.; Blennow, K.; Tarkowski, A.; Kumar, P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol. Aging 23:237-243; 2002.
111. Teismann, P.; Schulz, J. B. Cellular pathology of Parkinson's disease: Astrocytes, microglia and inflammation. Cell Tissue Res. 318:149-161; 2004.
112. Toborek, M.; Lee, Y. W.; Flora, G.; Pu, H.; Andras, I. E.; Wylegala, E.; Hennig, B.; Nath, A. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell. Mol. Neurobiol. 25:181-199; 2005.
113. Town, T.; Tan, J.; Flavell, R. A.; Mullan, M. T-cells in Alzheimer's disease. Neuromolecular. Med. 7:255-264; 2005.
114. van der Flier, M.; Hoppenreijs, S.; van Rensburg, A. J.; Ruyken, M.; Kolk, A. H.; Springer, P.; Hoepelman, A. I.; Geelen, S. P.; Kimpen, J. L.; Schoeman, J. F. Vascular endothelial growth factor and blood-brain barrier disruption in tuberculous meningitis. Pediatr. Infect. Dis. J. 23:608-613; 2004.
115. van der Wal, E. A.; Gomez-Pinilla, F.; Cotman, C. W. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. Neuroreport 4:69-72; 1993.
116. Verbeek, M. M.; Otte-Holler, I.; Westphal, J. R.; Wesseling, P.; Ruiter, D. J.; de Waal, R. M. Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am. J. Pathol. 144:104-116; 1994.
117. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H. K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535-541; 2002.
118. Webster, S.; Lue, L. F.; Brachova, L.; Tenner, A. J.; McGeer, P. L.; Terai, K.; Walker, D. G.; Bradt, B.; Cooper, N. R.; Rogers, J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18:415-421; 1997.
119. Wells, W. A.; Bonetta, L. Endothelial tight junctions form the blood-brain barrier. J. Cell Biol. 169:378; 2005.
120. Wisniewski, H. M.; Barcikowska, M.; Kida, E. Phagocytosis of beta/A4 amyloid fibrils of the neuritic neocortical plaques. Acta Neuropathol. (Berl.) 81:588-590; 1991.
121. Wong, D.; Dorovini-Zis, K.; Vincent, S. R. Cytokines, nitric oxide, and cGMP modulate the permeability of an in vitro model of the human blood-brain barrier. Exp. Neurol. 190:446-455; 2004.
122. Wyss-Coray, T.; Lin, C.; Yan, F.; Yu, G. Q.; Rohde, M.; McConlogue, L.; Masliah, E.; Mucke, L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7:612-668; 2001.
123. Wyss-Coray, T.; Masliah, E.; Mallory, M.; McConlogue, L.; Johnson-Wood, K.; Lin, C.; Mucke, L. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature 389:603-606; 1997.
124. Yang, S. P.; Bae, D. G.; Kang, H. J.; Gwag, B. J.; Gho, Y. S.; Chae, C. B. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol. Aging 25:283-290; 2004.
125. Zetterberg, H.; Andreasen, N.; Blennow, K. Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci. Lett. 367:194-196; 2004.
126. Zhao, C. H.; Ling, Z.; Newman, M. B.; Bahatia, A.; Carvey, P. M. TNF-alpha knockout and minocycline treatment attenuates blood brain barrier leakage in MPTP-treated mice. Neurobiol. Dis.; 2007.
127. Zipser, B. D.; Johanson, C. E.; Gonzalez, L.; Berzin, T. M.; Tavares, R.; Hulette, C. M.; Vitek, M. P.; Hovanesian, V.; Stopa, E. G. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol. Aging; 2006.
128. Zlokovic, B. V.; Deane, R.; Sallstrom, J.; Chow, N; Miano, J. M. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol. 15:78-83; 2005.